[go: up one dir, main page]

Waller et al., 1999 - Google Patents

Reteplase, a recombinant plasminogen activator

Waller et al., 1999

Document ID
5966922326265469668
Author
Waller M
Kohnert U
Publication year
Publication venue
Biopharmaceuticals, An Industrial Perspective

External Links

Snippet

Thrombolysis is now standard therapy for the treatment of acute myocardial infarction. However, evidence suggests that earlier treatment and more rapid and complete recanalization of infarct-related coronary arteries may lead to greater survival benefits than …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors

Similar Documents

Publication Publication Date Title
CA3008185C (en) Method for prevention or treatment of acute and chronic thrombosis
JP2631645B2 (en) Novel compound, production method thereof and pharmaceutical composition containing the same
HU218092B (en) Process for producing tissue-plasminogen activator derivative
EP0307847B1 (en) Thrombolytic agent
Smalling Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator
CN106890320A (en) It is a kind of for preventing or treating acute and Chronic Thrombotic method
WO2004037208A2 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
RU2143490C1 (en) Bifunctional variant of urokinase, plasmid containing synthetic structural gene encoding bifunctional urokinase, plasmid (variants), method of plasmid preparing, method of bifunctional variant of urokinase preparing, thrombolytic agent
CN103327996A (en) Composition for dissolving thrombi, and a pharmaceutical composition for treating stenotic or occlusive vascular diseases which comprises the same
Xu et al. Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment
Waller et al. Reteplase, a recombinant plasminogen activator
Thompson et al. Thrombolytic therapy in dogs and cats
Smalling A fresh look at the molecular pharmacology of plasminogen activators: From theory to test tube to clinical outcomes
US5854048A (en) Method for treating thromboembolic conditions using thrombolytically active proteins
Gaffhey Tissue plasminogen activator for thrombolytic therapy: expectation versus reality
CN1849133B (en) Intravenous administration of a non-neurotoxic plasminogen activator for the treatment of stroke
US5908625A (en) Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
CA2162986A1 (en) Proteins having fibrinolytic and coagulation-inhibiting properties
JP2904893B2 (en) Pharmaceutical preparations
Robinson et al. Redesigning t-PA for improved thrombolytic therapy
Hanna et al. Therapy with thrombolytic agents in coronary artery disease
US7271143B1 (en) Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy
EP0796323A1 (en) Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
JP2000504941A (en) Plasminogen activator can be activated by thrombin
US20200054719A1 (en) E-we thrombin analog and fibrinolytic combination